MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies announces results of its Annual Shareholders Meeting

Transparency directive : regulatory news

29/05/2015 17:46

Press release

MAUNA KEA TECHNOLOGIES ANNOUNCES RESULTS OF ITS ANNUAL SHAREHOLDERS MEETING

PARIS, (May 29, 2015) - Mauna Kea Technologies (NYSE Euronext: MKEA,
FR0010609263), inventor of Cellvizio(r), the multidisciplinary confocal laser
endomicroscopy platform, today announced the results of its Annual Meeting of
Shareholders, which was held on May 27th , 2015 in Paris under the chairmanship
of Sacha Loiseau, General Manager and board member and with a quorum of 45% of
the shares.

All resolutions supported by management we re approved except the 11th
resolution.

Shareholders approved the company's consolidated financial statements for the
year ended December 31, 2014.

For additional details, Mauna Kea Technologies invites its shareholders to refer
to the minutes of the Annual Shareholders Meeting, available on investor section
of the company's website (in French)

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on leading
innovation in endomicroscopy and optical biopsy. The company designs, develops
and markets innovative tools to visualize and detect cell abnormalities in real
time during standard gastrointestinal and pulmonary endoscopy procedures. The
company's flagship product, Cellvizio(r), a probe needlebased Confocal Laser
Endomicroscopy (pCLE/nCLE) system, provides physicians and researchers with
high-resolution cellular imaging of internal tissues. Large-scale,
international, multi-center clinical trials have demonstrated Cellvizio's
ability to help physicians to more accurately detect early forms of diseases and
make immediate treatment decisions. Designed to help physicians in their
diagnoses, provide patients with better treatment and reduce hospital costs, the
Cellvizio system can be used with virtually any endoscope. Cellvizio has 510(k)
clearance from the United States Food and Drug Administration and CE Marking in
the European Union for use in the gastrointestinal tract and the urinary and
respiratory systems, for endoscopic exploration of the biliary and pancreatic
ducts and for fine-needle aspiration procedures. Cellvizio has also obtained
SFDA regulatory approval in China and MHLW approval in Japan.

For further information on Mauna Kea Technologies, visit www.maunakeatech.com

NewCap.
Investor Relations Europe
Florent Alba
Tel: +33 (0) 144 71 94 94
maunakea@newcap.fr

MAUNA KEA TECHNOLOGIES's latest news

25/04/2024 20:50

MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies announces results of its Annual Shareholders Meeting

Transparency directive : regulatory news

MAUNA KEA TECHNOLOGIES's latest news

Other stories